Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069) Meeting Abstract
| Authors: | Hodi, F. S.; Postow, M. A.; Chesney, J. A.; Pavlick, A. C.; Robert, C.; Grossmann, K. F.; McDermott, D. F.; Linette, G. P.; Meyer, N.; Giguere, J. K.; Agarwala, S.; Shaheen, M. F.; Ernstoff, M. S.; Minor, D. R.; Salama, A. K.; Taylor, M. H.; Ott, P. A.; Jiang, J.; Gagnier, P.; Wolchok, J. D. |
| Abstract Title: | Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 488s |
| Language: | English |
| ACCESSION: | WOS:000404711507140 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.9518 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract : 9518 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
